reserved.
T understood. Both acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) are characterized by a block in the normal pattern of differentiation, leading to the accumulation of immature cells, either myeloblasts or lymphoblasts. Aberrant expression of a number of genes, including oncogenes, has been reported in acute leukemia, which may play a causative role in the transformed phenotype. Gene amplification at the DNA level or overexpression at the RNA level, due to increased transcription or prolongation of messenger RNA (mRNA) half-life in the cell, can result in the overabundance of a gene product. Conversely, the decrease or absence of a gene product could result from gene deletion or a mutation that alters the amount or activity or cellular localization of a protein.
Another type of genetic alteration, increasingly implicated in hematologic malignancies, is the inappropriate expression of transcription factors (TFs) or the creation of fusion mRNA transcripts and fusion TF proteins. TFs are nuclear proteins that recognize and bind specific regulatory DNA sequences and stimulate or repress transcription.'J They contain discrete transcriptional-activation domains and DNA-binding domains; some also contain regions critical for dimerization. Abnormalities in either the abundance or activity of these factors can result in inappropriate expression of genes critical to the processes of growth and differentiation. In this review, we will discuss TFs in general and then focus on specific chromosomal translocations that involve transcription factor genes and have been implicated in acute leukemia.
TF MOTIFS
Several classes of TFs have been identified based on their DNA binding and/or dimerization motifs (Fig 1) . A helixloop-helix (HLH) motif can be found in a number of TFs implicated in acute leukemia, including c-myc, lyl-1, tal-1, and E2A (Table l) , as well as MyoD and myogenin, necessary for myoblast differentiati~n.~ This motif consists of two amphipathic helices separated by a non-helical loop. Although originally thought to mediate DNA binding, the HLH structure mediates protein dimerization and facilitates the interaction between the adjacent basic DNAbinding motif and target DNA sequence^.^.^ The basic DNA-binding region contains basic amino acids and is present in HLH containing TFs (sometimes referred to as basic HLH [bHLH] factors) and in TFs containing a leucine zipper (LZ) dimerization motif (sometimes referred to as bZIP factors because of their basic DNA-binding motif and adjacent LZ motif). The DNA-binding region recognizes a specific regulatory DNA sequence and appears to also contain information required for tissue-specific gene activation. 6 Some members of the HLH TF family are expressed ubiquitously (eg, the E12/E47 proteins), whereas other members are expressed in a cell-specific manner (eg, MyoD). The HLH proteins can form homodimers' and also heterodimers,s often consisting of one ubiquitous and one cell-specific p r~t e i n .~ Homeobox domains, which consist of a highly conserved 60 to 61 amino acid region responsible for DNA binding, are found in another class of TFs? The homeoboxcontaining homeotic genes were originally identified in Drosophilia melanogaster; the proteins they encode have been shown to be critical to normal development, regulating the expression of a variety of genes in a temporal and spatial fashion.I0 These genes can act as both positive and negative regulators of transcription. Homeobox-containing proteins have been found in all species from yeast to humans and the homeodomains contain remarkable amino acid conservation across species, although the remainder of the proteins may be divergent. The homeobox is predicted to form a helix-turn-helix structure consisting of an a-helical region followed by a p-turn and then another a-helical region. This motif is used by a variety of prokaryotic TFs to bind DNA."
A third DNA-binding motif contained in TFs is the zinc finger motif.I2 Pairs of cysteine-cysteine residues or histidinecysteine residues bind a zinc molecule and form finger-like structures that interact with specific DNA sequences.
A NICHOLS AND NlMER
Generally, these finger-like projections occur in pairs, and are separated by a series of predominately basic and polar amino acids. Steroid hormone receptors contain zinc finger motifs; this family includes the glucocorticoid receptor, the estrogen and progesterone receptors, the vitamin D receptor, and the thyroid hormone family and retinoic acid family of receptors. 13 The zinc fingers of the steroid receptors are generally paired and each finger contains four cysteine residues. In contrast, the zinc fingers of the TFIIIa and Spl TFs contain both cysteine and histidine residues repeated multiple times throughout these proteins. The DNAbinding, ligand-binding, and transcriptional-activating domains of the steroid hormone receptors molecules function as discrete modules and multiple experiments have shown that swapping these domains between members of the steroid hormone receptor family still results in functional molecules. Such experiments allowed the identification of the ligand for what proved to be retinoic acid receptor a (RARa). 14915 LZ domains are responsible for dimerization of another class of TFs.16 This class of TFs contains leucine residues repeated every seven amino acids so that leucine residues occur on the same side of a helical structure every two turns of the DNA. Protein dimerization is mediated by the LZ motif and such interactions are critical for the DNAbinding and transcriptional-activating properties of these factors. Experiments have shown that replacement of the LZ region of the yeast TF GCN4 by a disulphide cross-link can generate dimers capable of sequence-specific DNA binding." Thus, the LZ structure appears to be important for proper positioning of TF dimers on the DNA. The LZ-containing TFs interact with the DNA using a coiledcoil structure rather than through the LZ motif itself.l8 TFs that contain LZs include cjun and c-fos. The c-j~n product can form homodimers and heterodimers with c-fos, and each has a different affinity for DNA.I9 The myc protooncogene proteins (c-myc, N-myc, and I-myc) and related TFs (TFEB, TFE3, AP-4, and USF) contain a basic DNA-binding region, an HLH motif, and a carboxy terminal LZ motif.*(' In the case of c-myc, both the LZ motif and the HLH motif are required for homodimer formation and for heterodimer formation with Max, another bHLH LZcontaining TF. 21 Transcriptional-activation domains have been identified in TFs that are distinct from the DNA-binding regions or dimerization domains. These activation domains interact with other protein components of the transcriptional apparatus (eg, RNA polymerase or the TF IID complex, which contains a TATA box binding factor) altering their structure or activity to generate an active transcriptional complex. One class of these domains contains a high proportion of acidic amino acids that are arranged in an a-helical structure with the negative charges aligned on one side of the helix.22 Other domains that are proline-richZ3 or glutamine-ri~h*~ have also been described. 
IDENTIFICATION OF TF GENES AS ONCOGENES
Studies with the c-jun proto-oncogene demonstrated for the first time that T F genes could serve as oncogenes. Transformed cells have higher levels of c-jun than do control cell lines, suggesting that the level of c-jun may play an important role in the transformed phenotype.2h The v-jun oncogene product (a gag-jun fusion protein) is the only viral protein found in ASV 17-transformed cells, raising strong suspicion that v-jun plays an important role in oncogenesis. The jun family of TFs includes c-jun, jun-B, and jun-D, which are members of the AP-1 family of transcriptional regulator^.^^^^^ AP-1-binding sites are sequence-specific regions of DNA (TGACTCA) that can confer the effects of the potent tumor-promoting phorbol esters (such as phorbol myristate acetate) on responsive genes and serve as the recognition site for c-jun homodimers or c-jun lc-fos heterodimers. The expression of the different members of thejun family varies from tissue to tissue and these factors can serve either as activators or as repressors of transcription, depending on the array of DNA-binding sequences and the other cellular factors present.
In one of the first studies implicating aberrant TF expression in leukemia, Morishita et alZ9 examined interleukin-3 (IL3)-dependent murine myeloid leukemia cell lines that could not be induced to differentiate. Three different IL-3-dependent lines had retroviral insertion into the same region of DNA, causing activation of transcription of a novel gene called Evi-1 (ecotropic virus integration site), which encodes a member of the zinc finger family of transcriptional regulatory proteins. Evi-1 is not normally expressed in hematopoietic cells and introduction of this gene into myeloid leukemia cell lines did not detectably alter the growth factor requirements of these cells, but it did alter their ability to differentiate.z9 Expression of Evi-1 has also been shown to block terminal differentiation of these cells in response to granulocyte colony-stimulating factor (G-CSF), providing further evidence of its effect on differentiation and its potential role in transf~rmation.~~ One of the major signposts directing molecular studies of human acute leukemia has been the distinct cytogenetic abnormalities associated with specific subtypes of acute leukemia.31 Consistent translocations have been reported in both myeloid and lymphoid malignancies. In lymphoid malignancies, the site of aberrant gene rearrangement has frequently been at the regions of Ig gene or T-cell receptor (TCR) gene recombination, and thus the most common breakpoints in B cells have been at chromosome 14q32 (heavy chain locus), 2p12 (K light chain locus), or 22qll ( h light chain locus).3z In T-cell malignancies, chromosomes 14qll and 7q35 have been the most frequent sites of translocations, involving the TCR a/6 locus and P l y locus, re~pectively.~~ In myeloid leukemias, the pattern of rearrangements is less clear from a functional point of view. The Philadelphia chromosome translocation t(9;22) that accompanies chronic myelogenous leukemia or acute lymphoblastic leukemia is the best characterized transl0cation,3~ involving rearrangement of the bcr and c-ab1 proto-oncogenes. The t( 15;17) that characterizes acute promyelocytic leukemia (APL)35 is also being intensively investigated at the molecular level (see below).
Studies implicating TF genes in human leukemias have also been reported. As detailed in this review, TF genes are frequently involved in gene rearrangements resulting from chromosomal trans location^.^^,'^ Most of the abnormalities identified thus far have been in the lymphoid leukemias, probably because the Ig genes and TCR genes can be used as probes to detect rearrangements or deletions. No such markers have been identified for the myeloid leukemias. But, thus far, nearly all classes of transcription factors have been implicated in either lymphoid or myeloid acute leukemia. Several of the known, characterized translocations involving TFs will be covered below. Three independent groups, using different approaches, discovered that the RARa gene was rearranged in patients with acute promyelocytic
The RARa gene, which is located on chromosome 17, is fused with a gene on chromosome 15 that has been designated PML (for promyelocytic leukemia gene). The breakpoint on chromosome 17 occurs within the first intron of the RARa gene, whereas two major breakpoint regions have recently been identified in the PML gene.45 This results in the creation of two fusion RNA species: PML-RARa, which encodes a fusion protein containing the N-terminus of the PML protein and the C-terminus of RARa protein, and an RARa-PML fusion encoding protein containing the N-terminus of RARa and the C-terminus of PML.45-47 Both fusion RNA species are present in all APL samples, suggesting that both may be pathogenetically important.
PML contains a putative zinc finger domain and appears to be a member of a newly recognized DNA-binding family of proteins (which includes rpt-1, a factor that can regulate
IL-2 receptor [IL-2R] and human immunodeficiency virus [HIV] expression$* as well as RING1, MEL-18 and Rag-1).
The PML gene appears to be uniquitously expressed, with multiple alternatively spliced f o r m~.~j -~~ The RAR genes encode members of the steroid hormone/ thyroid hormone receptor family of transcription factors. After binding retinoic acid, RARa, RARp, and RARy can bind to specific DNA sequences (retinoic acid-responsive elements) in the promoters of a variety of genes. A variety of nucleotide sequences can be recognized by the RARa gene product, but the half site AGGTCA is nearly always part of the DNA-binding element.49 Both homodimer and heterodimer formation (with other members of the steroid hormone receptor family) have been observed for the The discovery that the RARa gene is involved in the gene rearrangement resulting from the t(15;17) is intriguing, given the clinical response of patients with APL to all-trans retinoic acid. Eleven patients with APL received all-trans retinoic acid therapy in one study and nine entered a complete remission.41 All seven patients who underwent repeat karyotypic analysis had a normal karyotype during remission, but several of these patients with clinical complete remissions still had abnormal RARa mRNA transcripts detected, suggesting that the abnormal cell populations could mature normally under the influence of all-trans retinoic acid. Immunophenotyping and karyotypic analysis also demonstrated maturation of the neoplastic, CD33+ cells. Persistent RARa rearrangements were seen in maturing myeloid cells in another all-trans retinoic acid clinical
The clinical response of APL to all-trans retinoic acid in this study correlated with the presence of an abnormal RARa mRNA transcript; the one patient who failed retinoic acid therapy had a normal karyotype and normal RARa expression on Northern blot analysis.
Several studies have addressed the cellular basis for the R A R s .~'~ response of APL to all-trans retinoic acid. The ability of retinoic acid to induce the differentiation of HL-60 cells in vitro can be directly mediated by RARa.j3 In vitro studies looking at the ability of all-trans retinoic acid and the 13-cis retinoic acid to induce differentiation of APL blasts showed that 10-fold higher concentrations of 13-cis retinoic acid were required to observe maximal differentiation. Thus, one explanation for the clinical efficacy of all-trans retinoic acid could be the ability to achieve in vivo concentrations adequate to induce differentiati~n.~~ Consistent with this possibility is the observation that 1 3 4 retinoic acid at 100 mg/m2 can achieve occasional clinical responses. However, the different clinical effects of cis retinoic acid and all-trans retinoic acid may reflect their different activities on the PML-RARa fusion protein that is present in the leukemic cells.
On the molecular level, theories have been advanced to explain the response of APL to all-trans retinoic acid. The t( 15;17) translocation removes 49 N-terminal amino acids from the RARa molecule, but this deletion is not likely to contribute significantly to the abnormal activity of the fusion product because deletion of these amino acids did not alter the transactivating properties of an N-terminally truncated RARa compared with the wild-type RARa molecule. The PML-RARa fusion has been shown to have altered transactivation properties relative to the normal RARa46,47 and may act as a dominant negative oncogene, similar to v-erbA, which can block thyroid hormoneinduced erythroid d i f f e r e n t i a t i~n .~~.~~ The PML-RARa fusion product can suppress the basal transcriptionalactivating activity of RARa in the absence of retinoic acid, but it is superinducible in the presence of retinoic acid. Thus, one theory is that the PML-RARa fusion product blocks myeloid differentiation by antagonizing the effects of the normal RARa. However, it is also possible that the PML-RARa fusion product can act as an inhibitor of the endogenous PML pathway. This theory suggests that the t(15;17) translocation places the PML gene under the control of the RARa ligand-binding domain. The translocation may decrease the affinity of the fusion product's retinoic acid ligand-binding domain for retinoic acid so very high levels of retinoic acid are required for normal function of the PML gene. The fusion protein could form inactive homodimers or heterodimers and the addition of retinoic acid could activate the fusion molecule and reverse any inhibitory effects.
It is possible that dominant negative effects on the function of both the PML and the RARa gene products are pathogenetically involved in the transformation process. Additional studies are needed to understand the molecular mechanism interfering with cellular differentiation, but any theory must explain how administration of all-trans retinoic acid to patients with APL leads to cellular differentiation and frequent complete, although transient, clinical remission.
t(6;9); DEK/CAN
The t(6;9) (p23;q34) translocation, has been reported in young adult AML patients,j7 and may implicate another use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From transcription factor(s) in its pathogenesis. This chromosomal abnormality has been associated with a poor prognoand, although most of the patients have the M2 or m4 FAB histologic subtype, some have had M1 or M7 subtypes. Although the c-ab1 proto-oncogene is located on chromosome 9, the breakpoint on chromosome 9 is greater than 300 kb downstream from c-ab1,59 and when five patients with t(6;9) were studied, the breakpoints on chromosome 9 were clustered within an 8-kb region of an intron of a newly described gene called Cain (can).6O The can gene is large ( < 65 kb in size) and normally encodes a 7.5-kb mRNa and a 220-Kd protein. The function of the can gene product is unknown, but can mRNA is detectable in Daudi B cells, HL-60, KG-1, HeLa cells, and normal testis; K562 cells have amplification of the can gene with overexpression. A chimeric (fusion) 5.5-kb transcript has been identified in t(6;9) cellsm containing 5' sequences from the dek gene, which is located on chromosome 6, and 3' sequences from the can gene. Little is known about the function of the dek gene, but the dek gene breakpoints are contained in a 12-kb region and always occur in the same intron.61 Although dek is expressed in all mouse tissues,61 the deklcan fusion transcript is specific for the t(6;9) and consistently generates an identical 165-Kd DEKICAN fusion protein.
The C-terminal CAN amino acids, present in both CAN and DEKICAN proteins, may encode an ancillary DNAbinding region. Additionally, although DEK localizes to the cytoplasm, the DEKICAN product localizes to the nucleus.62 This circumstantial evidence suggests that DEKICAN may be involved in transcriptional events, although neither the fusion protein nor its normal counterparts have, as yet, been shown to be TFs.
TRANSLOCATIONS IN ALL
Several HLH TF genes have been identified at translocation breakpoints in ALL. Many of these genes are translocated to TCR genes resulting either in the inappropriate expression or overexpression of the TF or in the generation of a fusion protein. Approximately 26% of patients with T-cell all have a deletion of -90 kb of tal-1 genomic DNA (designated tald) that is not detectable by karyotypic analysis but still disrupts the tal-1 gene in a manner analogous to the t(1;14) transl~cation.~~ The tald deletion has been extensively characterized using the HSB-2 T-cell line. The coding sequences of the tal-1 (SCL) gene is retained in the fusion mRNA, but 5' untranslated SCL sequences are replaced by sequences from another gene called SIL (SCL interrupting locus). A chimeric SILISCL protein is not generated, but the control of SCL transcription is likely to be mediated through SIL sequences. Identical genomic rearrangements occur frequently in childhood T-cell ALL72 and are seen in other, unrelated T-cell lines despite the absence of a detectable cytogenetic abnormality.
The tal-1 gene product is a member of the HLH family and contains a basic DNA-binding domain and the HLH dimerization m~t i f .~~,~~ The t( 1;14) translocation breakpoint and the site of the tal-1 deletion both result in the loss of exon Ia, thus precluding the production of type A mRNA from the translocated or deleted allele (tal-1 has two alternative first exons Ia and Ib and encodes two different mRNA species designated type A and type B).72,7s This is reminiscent of the structural alterations of the c-myc gene that accompany the t(8;14) transl~cation.~~ The site specificity of the large tald deletion, and the precise DNA rearrangement that occurs, with heptamer and nonamer flanking sequences suggests that these deletions are mediated by the aberrant activity of a site-specific V-D-J DNA recombinases0SE1 resulting in the activation of the tal-1 locus, which is normally silent in T cells.73,75,76,s2 These deletion junctions are identical in various patients with T-cell ALL, suggesting that they are pathogenetically linked to the disease.
High levels of SCL/tal-1 expression (3.0-kb and 4.7-kb mRNA species) are seen in murine erythroid, mast cell, and some early myeloid cell lines. Differentiation of murine erythroid cell lines leads to an increase in SCL/tal-1 as a late events2 and SCL/tal-1 expression is also consistently seen in human erythroid cell lines. tal-1 mRNA is not seen in B-cell lines or myeloid cell lines,83 nor is tal-1 seen in use only.
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The tal-1 gene product can interact with the ubiquitous HLH-containing proteins E12 and E47.84 tal-1 and either E12 or E47 can form heterodimers that specifically recognize the Ig E-box transcriptional enhancer motif. In this manner, tal-1 can behave similarly to the muscle-specific HLH protein MyoD5 (which can also form heterodimers with ubiquitous HLH-containing proteins), although it is expressed in several cell types.
Disregulation of tal-1 by deletion or translocation may block normal T-cell differentiation and contribute to the malignant transformation of T cells.
t(7;19); lyl-1
The t(7;19) translocation seen in acute T-cell lymphoblastic leukemias5 involves the lyl-1 gene and the TCR p-chain gene locus, located at 7q35. The lyl-1 gene also encodes an HLH type protein, with some striking similarities to the tal-1 (SCL) protehx6 In the supT7 T-cell line, which carries the t(7;19) translocation, the breakpoint on chromosome 19 occurs in the first intron of the lyl-1 gene, resulting in the loss of the first exon of lyl-1 and likely its regulatory sequences as well. This rearrangement results in the juxtaposition of the second exon of lyl-1 with the TCR chain gene in opposite orientations. The truncated lyl-1 transcripts are actively transcribed, although a potential CTG initiation codon in exon 1 of the human lyl-1 gene is lost. Examination of the murine lyl-1 gene structures7 suggests that the lyl-1 coding sequences are not altered by the translocation. lyl-1 is expressed in most murine myeloid, erythroid, and B-cell lines, with little or no detectable expression of lyl-l in most T-cell lines.87 There is also little or no lyl-1 expression in the nonhematopoietic tissues examined thus far.82 Different size mRNAs can be seen (1.5 to 1.8 kb or 2.0 to 2.3 kb), resulting predominately from differential exon usage in the 5' untranslated region, and the expression of lyl-1 appears to be differently regulated in different hematopoietic cell types. The normal role of the lyl-1 gene product in hematopoiesis and its role in T-cell differentiation and proliferation remains to be elucidated. The related gene Ttg-2 (or rhombotin 2), which is located at llp13, is also at the site of a recurrent translocation in T cell ALL, and also involves the TCRS gene locus on 14q11.y4 The breakpoints on chromosome llp13 all map within a 25-kb region. The Ttg-2 gene, which is 48% identical to Ttg-l at the amino acid level, is overexpressed in t( 11;14)(p13;q11). Ttg-2 contains two LIM domains and is normally expressed in nervous tissue and in fetal liver, spleen, and kidney. It is not expressed in activated T cells and shows minimal, if any, expression in mouse thy mu^.^^.^^
The inappropriate expression of this gene may also be involved in the pathogenesis of lymphoid leukemia. For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From PRL). The homeodomain of PBX is distinct from previously described mammalian homeoboxes, but bears some homology to the yeast mating gene products MAT a1 and MAT a2. E2A-PBX fusion transcripts have been detected by reverse transcriptase PCR in the three 1;19-carrying T-cell lines mentioned above and in 37 of 38 patients with the translocation, demonstrating that the fusion transcripts (and the predicted chimeric protein) are nearly constant features of the t(l;19).lo1
Molecular analysis has shown that the breakpoint on chromosome 19 occurs in a very tightly clustered region in the intron between exons 13 and 14.1°2 The breakpoint region on chromosome 1 is much broader, although it also occurs within a single, large intron ( > 50 kb in length). Thus, although the breakpoints on chromosomes 1 and 19 may vary from patient to patient, the mRNAs generated by the translocation have the same sequences, suggesting that the site-specific fusion of E2A and PBXl is pathogenetically important. Subsequently, Kamps et allo3 have shown that retroviral expression of the chimeric p85 and p77 E2A-PBX proteins (which differ at their C-terminal ends) can transform NIH3T3 cells (p77 more efficiently), also making them tumorigenic in nude mice. PBXl expression is not detectable by Northern analysis in pre-B cells, but can be detected in a variety of cell types (fetal and adult) using PCR. Recently, several new members of the PBX family of TFs have been identified, PBX2 and PBX3, which appear to be ubiquitously expre~sed.'"~ The biologic characteristics of the EM-PBX fusion protein are not known, but its target specificity and the mechanism underlying its ability to transform cells are under investigation.
t(10;14) Hox 11 (TCL3)
Approximately 7% of T-cell ALLs are characterized by the t( 10;14)(q24;qll) t r a n s l o c a t i~n .~~~-~~~ Hatano et allo8 have demonstrated that this translocation results in the rearrangement of the homeobox-containing Hox 11 (previously called the TCL3 locus) gene with the TCRG chain gene. In all patients, the breakpoints on chromosome 10 are clustered within a 15-kb region, located centromeric to the Hox 11 coding sequences.107 A 2.1-kb Hox 11 mRNA was detected in normal human (or murine) liver tissue, but was not expressed in normal hematopoietic cells. The homeodomain of the human Hox 11 gene is most similar to its murine counterpart and also to the homeodomain of the murine HLX gene, which is expressed in hematopoietic The gene also shows significant homology with the Drosophila antennapedia genes. Hox 11 is the first homeobox gene implicated in T-cell neoplasia and its mechanism of activation of the transformed phenotype has yet to be elucidated. A variant translocation, t(7;10)(q35;q24), also involves the Hox 11 gene, resulting in the overexpression of the normal Hox 11 mRNA. This translocation involves the TCRP locus on 7q35 and is thought to arise from aberrant physiologic recombination. The breakpoint on chromosome 10 occurs 12 to 13 kb centromeric to the known breakpoints of the t(10;14).110 Hox 11 mRNA is detectable only in T-cell lines carrying the t(10;14) or t(7;lO) translocation; however, breakpoints in the 10q24 cluster region have been seen in pre-B-cell ALL.lo7 Unlike the situation with the E a -P B X homeobox rearrangement, Hox 11 is not expressed as a fusion transcript.
Another homeobox gene, Hox 2.4, has been implicated in murine leukemia. The WEHI3B murine myelomonocytic leukemia cell line constitutively expresses both Hox 2.4 and IL-3 due to insertion of a proviral intracisternal A particle upstream of these genes.111J12 When normal murine bone marrow cells were infected with retroviruses carrying the genes for IL-3 or both IL-3 and Hox 2.4, only the retrovirus containing both Hox 2.4 and IL-3 was highly leukemogenic.lI3 Cells infected with the Hox 2.4 and IL-3 genes showed retarded differentiation in vitro, generated myelomonocytic cell lines, and produced a transplantable myeloid leukemia in vivo. It appears that expression of Hox 2.4 can impede the IL-3-driven differentiation process of myeloid cells. 113 Although neither NIH3T3 cells nor BALB/C 3T3 fibroblast lines were transformed by infection with the IL3/Hox 2.4 virus in this system, overexpression of an I N -H o x 2.4 construct did render NIH3T3 fibroblasts tumorigenic in nude mice.lI4
The Hox gene complexes are located on chromosomes 2, 7, 12, and 17.1° The Hox gene complex located on chromosome 17 does not appear to be involved in the t(15;17) translocation in APL, but other chromosomal abnormalities involving 17, such as inversion 17, can be seen in AML. The Hox complex on chromosome 7 has also not yet been implicated in any hematologic malignancy, but chromosome 7 abnormalities (including monosomy 7 and 7q-) are seen in myeloid leukemias, especially in therapy-related leukemias and leukemias occurring secondary to occupational exposure.115 It is possible that Hox genes can be involved in molecular events within leukemia cells without being translocated, either by deletions or mutations that alter their activity. Hox 2.3 expression has been demonstrated in I662 cells, an erythroleukemia cell line derived from a patient with chronic myelogenous leukemia, and in four macrophage cell lines, although not in any of the myeloid cell lines examined.I16 Further studies will determine whether this homeobox gene or other Hox genes play a role in leukemogenesis.
SUMMARY
The frequent occurrence of TF gene involvement in translocations associated with leukemia is remarkable, although not yet explained. The wide variety of TFs involved in these translocations and the different stages of cellular maturation argue against a unifying mechanism. Recombinases, active during B-cell and T-cell development, have been implicated in gene arrangements involving TCR genes and in the SIL/SCL rearrangement, which involves two genes not normally rearranged. However, other mechanisms must clearly be active in generating these molecular abnormalities and perhaps they relate to the multistep maturation and differentiation processes and continuous cell turnover seen in hematopoietic cells.
The difficulties in obtaining human solid tumor samples may make it more difficult to identify translocations involving TF genes in solid tumors. Recently, the cytogenetic use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From analysis of solid tumors has improved and specific cytogenetic abnormalities have been associated with specific types of tumors. With advanced techniques, such as fluorescent in situ hybridization (a technique that does not depend on cell growth) and PCR, abnormalities involving TF genes will be discovered. Abnormalities of TF genes, other than translocations, have been seen in a broad variety of nonhematopoietic malignancies. The p53 protein has been shown to bind DNA in a sequence-specific fashion and interact with a variety of DNA tumor virus oncoproteins. The broad range of cell types that harbor p53 abnormalities suggests that TF abnormalities will likely be implicated in many solid tumors.
We have detailed several examples of how gene rearrangements that accompany chromosomal translocations in acute leukemia can alter the expression or activity of cellular TFs. Several translocations generate fusion RNA transcripts and fusion TF proteins with altered functional characteristics. Other translocations result in the expression of a gene not normally detectable in hematopoietic cells or alter the level of its expression, or affect the promoter usage or exon structure of the gene ( Table 2) . Studies are underway in many laboratories to characterize the biologic activity of these abnormal TFs and it remains to be proven that these molecular abnormalities are directly linked with leukemogenesis.
The identification of abnormal fusion transcripts and proteins may allow specific therapies to be directed against "tumor-specific'' DNA, mRNA, or protein targets. Therapeutic strategies based on antisense or ribozyme technology may be used to turn off expression of these genes and inhibit leukemia cell growth. Immunologic methods can also be used to direct therapy against the malignant cells.
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NOTE ADDED IN PROOF
The t(11;22)(q24;q12) translocation that accompanies Ewing's Sarcoma and related subtypes of primitive neuroectodermal tumors has been recently shown to generate a fusion transcript containing human fli-1 sequences (a member of the ets family of transcription factors) and sequences from the EWS gene."' A fusion transcript generated by the t ( 17;19) 
